At a glance
ClinicalIndex Comparison RecordN/ACompleted· 194 enrolled
Drug / intervention
CERENOVUS ENTERPRISE 2 Intracranial Stentdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Implantation of CERENOVUS ENTERPRISE 2 Intracranial Stent in Patients With Severe Symptomatic Intracranial Atherosclerotic Stenosis: A Multicenter, Prospective and Single-Arm Study in China
In Brief
A clinical study evaluating CERENOVUS ENTERPRISE 2 Intracranial Stent for Intracranial Atherosclerosis. Completed, enrolled 194 participants across 14 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and effectiveness of CERENOVUS ENTERPRISE 2 intracranial stent implantation in treatment of participants with severe symptomatic intracranial atherosclerotic stenosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIntracranial Atherosclerosis
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
2023202420252026
First PostedApr 2022
Enrollment StartMay 2022
Primary CompletionDec 2025
Study CompletionFeb 2026
TodayJul 2026
First PostedApr 7, 2022
Enrollment StartMay 24, 2022
Primary CompletionDec 24, 2025
Study CompletionFeb 6, 2026
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 4.2 years ago
Interventions
CERENOVUS ENTERPRISE 2 Intracranial Stentdevice
CERENOVUS ENTERPRISE 2 Intracranial Stent will be used to treat severe symptomatic intracranial artery stenosis.